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                 ABSTRACT 
 
Metastatic Melanoma, the fifth most common cancer in the western countries and the most common malignancy 
diagnosed in United States present itself as the most lethal treatment resistant cancer worldwide. In addition to the 
reactive oxygen species(ROS), mutations in the genes encoding receptors and non-receptor tyrosine/serene/threonine 
protein kinases are known to be involved in its etiology. Kinases are molecular players of cell survival, growth, and 
proliferation and migration that mediate their effects via various signal transduction pathways. A number of such 
molecular players have been previously found to be mutated and hyper phosphorylated in melanoma. Although, 
several systemic therapies including cytotoxic chemotherapy, targeted drugs, hormonal therapy, radiation therapy, 
bio-chemotherapy, and therapies that inhibit negative regulation of immune system have been approved from U. S. 
Food and Drug Administration (FDA) for metastatic melanoma treatment. However, no systemic therapy has 
meaningfully changed its survival end points so far and surgery still presents primary treatment option for advanced 
and metastatic melanomaa due to its highly resistant nature towards systemic drugs, high rate of severe, life-
threatening, or fatal side effects, and un satisfactory overall response rate. Therefore, there is still a need to develop 
therapies that target the unique molecular profile of melanoma tumors.  
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Basic Notions of Melanocytes and Melanoma Biology 
 
Melanoma originates from melanocytes. It is one of the most 
dangerous, drug-resistant, and highly metastatic skin cancers 
(Bandarchi, Jabbari, Vedadi, and Navab, 2013). The 
melanocytes transform into melanoma cells under the influence 
of various chemical, environmental, and genetic factors. ROS 
act on melanocytes as they are released from their primary stem 
cell pool, and also act during their proliferation (Bisevac et al., 
2018; Dayem et al., 2018). Genome-wide sequencing 
approaches have revealed that melanoma includes a complex 
of thousands of “passenger” and “driver” mutations comprising 
changes in DNA methylation, deletions, translocations, and 
amplification (Bandarchi, Navab, Seth, and Rasty, 2010). 
Approximately 50% of the transformed cells contain mutation 
in the BRAF gene that encodes a threonine/ serine kinase, 
which is a component of the MAP kinase pathway that controls 
cell growth (Ho, Jonsson, and Tsao, 2017). BRAF mutation 
results in hyperphosphorylation of MAP kinases activity, 
subsequently leading to uncontrolled growth of melanoma cells 
(Pons, and Quintanilla, 2006). However, together with BRAF 
mutation, melanocytes also undergo mutations in the genes of 
two important cell cycle regulatory proteins, p16INK4A and 
p14ARF, to acquire full cancerous phenotype. Both of these 
proteins, encoded by CDKN2A gene, are found to be deleted 
in almost 16–41% of sporadic melanomas, constituting 2nd 
highest penetrance genetic alteration. Hence, deletion, 
promoter silencing or mutation in CDKN2A gene inactivates 
its function and leads to unregulated cell growth. The CDK4 
gene mutation is the third most important high penetrance 
mutation. Proteins encoded with CDKN2A and CDK4 regulate 
cell cycle. Therefore, mutation in these genes disturbs the 
G1/S-phase checkpoint with a subsequent dysregulated cell 
growth (Sanches, Almeida, and Freitas, 2018). All these 
genetic and environmental changes are considered important 
for the transformation of melanocytes from healthy phenotype 
to tumor phenotype (Satyamoorthy and Herlyn, 2002).  
 
Melanoma, Survival, and Proliferation 
 
In the later stage of melanoma progression, the genetically and 
environmentally modified genes that encode kinases become 
part of a pathway that controls melanoma survival and 
proliferation. Indeed, in most melanomas, the CDK4 pathway 
is dysregulated either due to the loss of p16INK4A gene, or as 
a consequence of ERK hyerphosphorylation that initiates the 
RAS–RAF–MEK–ERK pathway, and stimulates cell cycle 
progression. The latter is an important contributor to melanoma 
evolution (Xu and McArthur, 2016). However, identification 
of ideal pathways to be used as therapeutical targets for 
maximal clinical benefit in melanoma patients remains a 
challenge.  
 
 
 
 
The Kinases as Molecular Players of Melanoma Cell Survival, 
Proliferation, and Metastasis  
 
The enzymes kinases responsible for phosphorylation reactions are 
either transmembrane receptors or cytosolic proteins. There are 518 
putative kinases in the human genome, out of which 90 are “tyrosine 
kinases” (PTKs) and 428 are “serine/threonine kinases” (PSKs) 
(Angus, Zawistowski, and Johnson, 2018). In signal transduction 
pathways, kinases catalyze phosphorylation reactions in a well-
orchestrated manner. The deregulation of this cascade leads to 
changes in survival, proliferation, and migration of normal body 
cells, and results in various ailments, including many cancer types 
(Nishi, Shaytan, and Panchenko, 2014). 
 
Phosphorylation, is the most abundant post-translational 
modification in eukaryotic proteins, it is the process of addition of 
phosphate (PO43-) group to a protein, with consequent 
conformational changes in its structure. The hydrophobic group of 
an amino acid residue, when esterified with phosphate (PO4
3-) can 
turn a hydrophobic part of a protein into a polar one. The consequent 
changes of protein dynamics via distant allosteric interactions 
within the protein cause proteins to become activated or deactivated 
(Kemp, 2018). Although lipid, sugars, and other biological 
macromolecules have a tendency to give up or take-up (PO43-) 
groups, only proteins are biological macromolecules that are 
abundantly phosphorylated as between one third to two thirds of the 
proteome is found to be temporarily phosphorylated in eukaryotes 
(Sacco, Perfetto, and Cesareni, 2017). 
 
Tyrosine, serine, threonine, and histidine residues of proteins are 
subjected to phosphorylation in eukaryotes whereas there are some 
other amino acid residues that become phosphorylated in 
prokaryotes (Grangeasse, Stülke, and Mijakovic, 2015; Krebs and 
Beavo, 1979; Cain, Solis, and Cordwell, 2014). Serine is the most 
commonly phosphorylated residue, followed by threonine. Tyrosine 
phosphorylation is rare in most eukaryotes. However, 
phosphorylation of tyrosine residues is the key step in many protein 
phosphorylation signaling pathways (e.g., in tyrosine kinase-linked 
receptors) (Pearson and Kemp, 1991). Phosphorylation and 
dephosphorylation are critical for regulating the functions of many 
cellular processes. Although phosphorylation regulates many 
biochemical and pathophysiological processes, it is also involved in 
the thermodynamics of energy-requiring reactions, protein-protein 
interactions via recognition domains, and enzyme inhibition, and 
also plays a role  in protein degradation (Bononi et al., 2011; Cheng, 
Qi, Paudel, and Zhu, 2011). All these events occur by switching on 
and off various signal transduction pathways of normal cell 
metabolism, transcription, cell cycle progression, cell survival, 
rearrangement of cytoskeletan, cell migration, apoptosis, and cell 
proliferation (Day, Sosale, and Lazzara, 2016; Nishi, Shaytan, and 
Panchenko, 2014). 
 
Tyrosine Specific Protein Kinases 
 
These enzymes are either present in the cell as cytosolic enzymes or 
on plasma membranes as receptors to phosphorylate only, the 
tyrosine amino acid residues of substrate proteins. 
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Receptors Tyrosine Kinase 
Platelet Derived Growth Factor Receptor (PDGFR) 
 
PDGF receptors are cell surface kinase receptors that are 
activated with the binding of their cognate ligand, the platelet 
derived growth factor (PDGF). Activated PDGFR dimerizes, 
and activates various intracellular cytosolic kinases by 
autophosphorylation. subsequently, signal transduction 
pathways are activated, for instance, PI3K pathway, MAP kinase 
pathway mTOR, and SFKS pathway (Fig. 1.1). All these 
pathways ultimately regulate cell cycle, cell growth, survival, 
cell prolifearion and cell migration by effecting gene expression. 
PDGFRs have been identified as two types that bind with 
different PDGF; PDGF-BB, and PDGF-AB (Kumar et al., 
2017).  
 
Tyrosine 751 phosphorylation site of PDGF-β that resides in the 
cytosol, autophosphorylates when the receptor binds with its 
cognate ligand. This tyrosine 751 residue binds with PI3K with its 
regulatory subunit p85. Upon tyrosine 751 phosphorylation, PI3K 
becomes activated, and converts PIP2 into PIP3, enhancing the 
PI3-AKT pro survival pathway for a normal cell growth (Szöőr et 
al., 2016). 
 
Epidermal Growth Factor Receptor (EGFR) 
 
EGF-receptor is a transmembrane protein. Epidermal growth factor 
(EGF), and transforming growth factor α (TGFα) are specific 
ligands of (EGFR) that bind with EGFR and activate it. Upon 
ligand binding, EGFR forms an active homodimer from inactive 
monomeric form (Fig. 1.1) (Wee and Wang, 2017).  
 
 
 
Fig. 1.1: Platelet-derived growth factor receptor (PDGFR) and Epidermal growth factor receptor EGFR activation. In both normal 
and cancer cells, PDGFR and EGFR exists in monomeric protein form; on binding to their cognate ligand, these monomers form dimers, 
and autophosphorylate each other on multiple tyrosine residues at their cytosolic sites. The phosphorylated tyrosine residues provide docking 
sites for many proteins of different signal transduction pathways of cell survival, proliferation, and migration. 
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Dimerization stimulates intrinsic intracellular protein-tyrosine 
kinase activity with subsequent auto-phosphorylation of several 
tyrosine (Y) residues (Addison, 2014).  When tyrosine residues, 
including Y992, Y1045, Y1068, Y1086, Y1148, and Y1173 of the 
C-terminal EGFR auto-phosphorylate, they serve as docking sites 
for other downstream proteins of several signal transduction 
cascades, principally the MAPK, STAT, PI3K, and MSK mTOR 
pathways, leading to DNA synthesis, cell migration, adhesion, and 
proliferation (Wee and Wang, 2017). 
 
Non-receptors Tyrosine Kinase 
The Src Family of Protein Tyrosine Kinases (SFKs) 
 
These are membrane-associated non receptor tyrosine kinases with 
proto-oncogen and signal transduction regulatory activity. This 
family of kinases comprises of thirteen members, including: Yes, 
Fyn, Fgr, c-Src, Yrk, Frk, Lyn, Blk, Hck, FAK, and Lck, all of 
them regulate signal transduction pathways through various cell 
surface receptors: adhesion receptors, receptor tyrosine kinases, G-
protein coupled receptors, and cytokine receptors in the context of 
multiple cellular environments (Espada and Martin-Perez, 2017; 
Vlaeminck-Guillem, Gillet, and Rimokh, 2014). Most studies are 
based on the PDGFR and EGFR tyrosine kinases receptors (Lewis-
Tuffin et al., 2015). When SFKs are stimulated by these receptors, 
they phosphorylate specific tyrosine residues in other proteins 
involved in cell survival, cell growth, invasion, migration, and 
metastatic signal transduction pathways. Therefore, these kinases 
act as important intermediaries of signal transduction pathways of 
both cancerous and non cencerous cells. The phosphorylation of C-
Src family of proteins are linked to cancer progression by 
promoting, dysregulated growth survival, invasion, and migration 
(Sen and Johnson, 2011).  
 
Serine/Threonine-protein Kinase (Chk-2) 
 
This threonine/serine-protein kinase, which is a versatile effector 
that arrest checkpoint-mediated cell cycle, is involved in DNA 
repair and apoptosis when cell undergoes uncontrolled growth 
(Zannini, Delia, and Buscemi, 2014; Xu, Tsvetkov, and Stern, 
2002). Chk-2 resides as non-active monomeric form in the nucleus 
during normal cell growth. However, ATM phosphorylates T68 
and other residues of Chk-2 following DNA damage; this 
phosphorylation changes the conformation of Chk-2 kinase with 
subsequent dimerization. Dimerization promotes 
autophosphorylation of T383, T387, S516, and S260, T432 
residues of its T-loop and kinase domain, respectively (Wu and 
Chen, 2003). Additional conformational changes dissociate the 
Chk-2 dimers into fully active monomers. Once Chk-2 is activated, 
it functions to phosphorylate numerous effectors including some 
phosphatases like CDC25A, CDC25B, and CDC25C. 
Phosphorylation of phosphatases by Chk-2 kinase inhibits their 
activity. Most importantly, phosphorylated CDC25 phosphatase 
blocks cell cycle progression by inhibition of CDK-cyclin complex 
tyrosine phosphorylation. In this way, it regulates cell cycle 
checkpoint arrest (Sur and Agrawal, 2016). Although in human 
melanoma P53 mutations are rare, melanoma cells still avoid  
 
 
apoptosis by over expressing a p53 negative regulator MDM4, 
that binds with p53 and halts its tumor suppressor activity. 
Approximately 65% of MDM4 were found to be upregulated in 
stage I-IV human melanomas. Chk-2 kinase phosphorylates 
MDM4, thereby reducing the degradation of p53, and controls the 
transcription of pro-apoptotic genes through phosphorylation of 
the transcription factor E2F1 (Gembarska et al., 2012). 
Furthermore, Chk-2 kinase phosphorylates Ser-20 p53, thereby 
disrupting the binding between p53 and its other negative 
regulator MDM2, and leading to the accumulation of free active 
p53 in cell cytosol. Later on, p53 translocates into the nucleus, and 
transcribes genes involved in the apoptosis (Zannini, Delia, and 
Buscemi, 2014). 
 
Other Molecules under Investigation in Melanoma 
Pathogenesis 
 
Together with these oncogenic pathways, there are several other 
molecules including P27, c-KIT, melanoma tumor antigen p97 
(melanotransferrin; MFI2/MTf), p53 and HSP that also play 
crucial roles in melanoma progression. 
 
Tumor Protein p53 
 
The tumor suppressor transcription factor p53 is a master 
regulator of cell growth. During different cellular stress situations, 
p53 either accelerates the DNA repair by inhibiting cell cycle 
progression or in case of damage, unrepaired cells initiate 
apoptosis by up-regulating the respective genes (Farnebo, Bykov, 
and Wiman, 2010). P53 stabilization and function has been known 
to be regulated by phosphorylation via intracellular serine and 
threonine kinases at many different serine, and threonine residues, 
including serine 15, 46, and 392 residing at N- and C-terminal 
regions of the protein. Phosphorylation at the CK2 site S392 of 
the p53 is take place following UV irradiation (Ashcroft, and 
Vousden, 1999). Phosphorylation of S46 of the p53, on the other 
hand, is proposed to regulate the pathways in response to DNA 
damage. S46 Phosphorylation site has been known to be regulated 
by several kinases, such as p38 mitogen-activated protein kinase 
(p38 MAPK) or AMP-activated protein kinase catalytic subunit α 
(AMPKα). Thus, for the regulation of normal cell function, 
phosphorylation of p53 might be a vital modification (Smeenk et 
al., 2011). 
 
Heat shock proteins (HSP)  
 
In response to stress conditions like exposure to cold, temperature, 
UV light, oxidative stress, wound healing, tissue remodeling, cells 
express stress specific proteins, termed heat shock proteins 
(Lianos et al., 2015).  Heat shock proteins are also expressed 
during certain diseases such as gastric cancers, hepatocellular 
carcinoma, breast cancers, lung cancers, and colonic tumors. This 
kind of proteins often shows chaperone function, as they aid to 
correct the folding of protein that are previously damaged by the 
stress conditions, thereby helping them to be stabilized (Tkacova 
and Angelovicova, 2012).   
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 Heat shock proteins 27 (HSP 27) 
 
Small molecular chaperone HSP27 is found as large oligomers in 
non-stressed cells. During stress phosphorylation of HSP27 
dissociates HSP27 oligomers into active dimers that provide cell 
cytoprotection by modulating reactive oxygen species via raising 
glutathione levels (Belhadj Slimen et al., 2014). Phosphorylated 
HSP27 is also found to oppose TNF-α-induced apoptosis by 
activation of transforming growth factor factor β-activated kinase 1 
(TAK1) and TAK1-p38/ER K pro-survival signaling (Katsogiannou, 
Andrieu, and Rocchi, 2014). Phosphorylated HSP27 has found to 
induce invasion, enhance cell proliferation, and suppresses Fas-
induced apoptosis in human PCa cells. Dephosphorylation of HSP27 
has been shown its significant role in actin reorganization, and 
inhibition of cell adhesion (Lee et al., 2008). Therefore, the approach 
of HSP27 dephosphorylation has been used for the development of 
HSP-targeting/ HSP27 dephosphorylating agents for the treatment of 
many pathological conditions, such as oncogenesis, 
neurodegeneration, and senescence (Hajer et al., 2017). 
 
Melanoma Signaling Pathways  
MAPK Signaling Pathway 
 
Mitogen activated protein kinase (MAPK) signal transduction 
pathway comprises kinases such as RAS, RAF, MEK, and ERK 
These kinases are activated when receptor tyrosine kinases (RTKs) 
bind to their ligands on the cell membrane (Fig. 1. 1). ERK signaling 
is also stimulated by adhesion signals via integrins (Paluncic et al., 
2016). Signals are transmitted to inactive membrane localized GDP-
bound RAS, convert it into an active GTP-bound RAS. The activated 
form of RAS that can potentiate cell survival by activating PI3K-
AKT signaling, or it can phosphorylate and activate RAF (RAF-1, 
BRAF, and ARAF). The activated RAF phosphorylates ERK1/2, and 
dissociates it from the MAPK complex. The activated ERK1/2 then 
translocates it into the nucleus with increased expression of an arry 
of genes of nuclear transcription factors, such as c-MYC and cyclin 
D1 leading to cell proliferation, differentiation, and survival 
(Inamdar et al., 2010). In melanocytes, MAPK pathway is tightly 
regulated. However, in melanomas, due to the BRAF and RAS 
mutation or other genetic or epigenetic modifications, the MAPK 
pathway is hyper phyphorylated and activated. This leads to the 
promotion of uncontrolled development of melanoma, cell survival 
and cell proliferation. Therefore, the MAPK pathway has been the 
focus of intense investigation in the field of oncology as a potentially 
important therapeutic target (Amaral et al., 2017). 
 
PI3K/AKT /PTEN Signaling Pathway 
 
This pathway is involved in melanoma proliferation, and 
metabolism. The kinases of this pathway are highly conserved 
phosphatidylinositol‐4,5‐bisphosphate 3‐kinase (PI3K).(Paluncic et 
al., 2016). Binding of insulin-like growth factor-1 (IGF-1) receptor 
with its ligand, insulin-like growth factor-1, results in the 
phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2), to 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), which then 
functions 
  
as a binding place for 3-phosphoinositide-dependent protein kinase 
1(PDK1) which activates the protein kinase B along with several 
other kinases (Siroy, Davies, and Lazar, 2016). Protein kinase B, 
also known as AKT, and a crucial effector protein, has three 
isoforms (AKT1, AKT2, and AKT3). AKT3 is frequently activated 
in melanoma. AKT3 activation may result in phosphorylation of up 
to 100 target proteins (Risso et al., 2015), including p70 ribosomal 
S6 protein kinase (S6K), glucocorticoid-dependent kinase (SGK), 
p90 ribosomal protein S6 kinase (RSK), and atypical PKC 
isoforms. Glycogen synthase kinase 3 beta (GSK3β) is one of the 
substrates of p-AKT that loses its kinase activity after 
phosphorylation by p-AKT. One of the phosphorylation targets of 
GSK3β is β-catenin that is not phosphorylated when GSK3β has 
lost its kinase activity. Hence, unphosphorylated β-catenin 
translocates and accumulates in the nucleus and subsequently up-
regulates the expression of c-MYC and cyclin D1 oncogenic genes. 
In addition, AKT can be completely phosphorylated, and activated 
by the mammalian target of rapamycin (mTOR). The 
phosphorylated AKT can also phosphorylate and activate ERK 
with a consequent increased in the expression of c-MYC. The 
phosphorylated AKT mediates anti-apoptotic effect by these 
regulatory mechanisms, leading to cancer progression (Manning 
and Toker, 2017). However, a component of MAPK signaling, i.e., 
oncogenic, small GTPase RAS, is also known to be a positive 
upstream regulator of the PI3K pathway. Active PI3K activates two 
diverse but interrelated pathways: the RAF–MEK–ERK pathway, 
and the PI3K-AKT signaling pathway. The latter provides 
activation of AKT, and its downstream targets. The PI3K-AKT 
pathway also stimulates anabolism, while the RAF–MEK–ERK 
pathway is more important in proliferation, and invasion (Gomes 
and Blenis, 2015). 
 
The JAK-STAT Signaling Pathway 
 
Signal transducer and activator of transcription (STAT) forms a 
latent intracellular transcription factor family of proteins. The 
STATs family of protein includes STAT1, STAT2, STAT3, 
STAT4, STAT5α, STAT5β, and STAT6. These transcription 
factors reside within the cytosol in monomeric, non-
phosphorylated form (O’Shea et al., 2015). Non-phosphorylated 
STATs become activated in response to stimulated cells with 
growth factors or cytokines receptors after binding with their 
cognate ligands. This binding results in dimerization of these 
receptors, and activation of the intrinsic receptor tyrosine kinase, 
together with receptor-associated tyrosine kinase JAKs, and Src-
activated STAT. Furthermore, these kinases can subsequently 
phosphorylate the receptor cytosolic tail. This phosphorylation 
creates a docking site where monomeric non-phosphorylated 
STAT and Src recruits them via their SH2 domain, and thereby 
themselves become substrates for tyrosine phosphorylation 
(Aittomäki, and Pesu, 2014). In addition to the activation of STAT 
via receptor-associated tyrosine kinases (JAKs and Src) by both 
growth factors, and cytokine receptors, Src and Abl phosphorylate 
STATs in a receptor independent reaction (Berger et al., 2014). 
Phosphorylation of STAT monomers induces dimerization, and 
subsequent translocation to the nucleus, where the dimers regulate  
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 gene expression after binding to STAT DNA-response elements. 
By this mechanism the STATs family of protein are supposed to 
up-regulate the apoptosis inhibitors genes (Bcl-xL, Mcl-1), cell 
cycle regulators (cyclins D1/D2, c-Myc), and inducers of 
angiogenesis (VEGF). They are also considered to participate in 
oncogenesis through their antiapoptotic effects, as well as 
proliferation, and angiogenesis (Miklossy, Hilliard, and Turkson, 
2013). 
 
MSK Signal Transduction Pathway 
 
The mitogen- and stress-activated kinases-1 and -2 (MSK1, and 
MSK2) serine/ threonine kinases are required to activate bZIP 
cellular transcription factor cAMP response element-binding 
protein (CREB) by phosphorylating it on Ser133 residue. 
Numerous genes of cell proliferation, cell survival, 
memory, glucose homeostasis, and spermatogenesis are 
transcribed when CREB binds to their promoter sequences 
(Kar et al., 2017). However, MSK1/2 is itself activated after 
phosphorylation by two mitogen-activated protein kinases 
(MAPKs). MAPKs are intracellular transducers of signals for 
mediating signals from numerous physiological stimuli, 
resulting in the regulation of a broad array of cellular 
responses. These ubiquitous and major MAPK families regulate 
a plethora of physiological processes by controlling the function 
of hundreds of cellular proteins via phosphorylation, either 
directly or via other kinases such as MSK (Duda and Frödin, 
2013). 
 
Mammalian Target of Rapamycin (mTOR) Signal 
Transduction Pathway 
 
“Mechanistic Target of Rapamycin” (mTOR) is a serine/ 
threonine member of the phosphatidylinositol 3-kinase-related 
kinase family. It is an enzymatic complex of two distinct proteins, 
i.e., mTOR complex 1 (mTORC1), and mTOR complex 2 
(mTORC2). Due to the core component of two distinct 
complexes, mTOR exhibits dual actions. mTOR functions as a 
cell growth regulator in the form of mTORC1, and as a regulator 
of cell survival in the form of mTORC2. (Gaubitz, Prouteau, 
Kusmider, and Loewith, 2016). The activity of mTORC1 is 
regulated under the influence of various inputs, including certain 
mechanical stimuli, insulin, rapamycin, growth factors, 
phosphatidic acid, certain amino acids, and their derivatives (e.g., 
L-leucine and β-hydroxy-β-methylbutyric acid), and oxidative 
stress, resulting in transcription of genes responsible for protein 
synthesis. Eventually, by controlling protein synthesis it 
regulates cell proliferation, and cell survival. Altogether, 
mTORC1 functions as a nutrient/energy/redox sensor. Moreover, 
mTORC1. also regulates the transcription of genes of lipid 
synthesis. It also has a role in cell motility, and autophagy (Kim, 
Buel, and Blenis, 2013).  
 
Together with various stimuli, the function of mTORC1 is 
regulated by its negative regulator p70 ribosomal protein S6 
kinase (p70S6K) that is itself a serine/threonine kinase.  
 
  
 
 
Normally, this kinase stays bound to mTORC1, and halts its 
activity. However, in response to cell proliferation and survival 
stimuli, its PRAS40 becomes phosphorylated, and dissociates 
from mTORC1, allowing it to function in protein, ribosomes, 
nucleotide, lipid synthesis, and in promoting cell growth, and 
blocking autophagy (Völkers and Sussman, 2013). 
 
mTORC2 is known to regulate AKT kinase by 
phosphorylating serine 473 of AKT/PKB. Phosphorylation of 
serine 473 by mTORC2 induces AKT phosphorylation on 
threonine 308 by PDK1, and leads to complete AKT 
activation. Fully activated AKT regulates cell survival, and 
metabolism (Rad, Murray, and Tee, 2018). In tumor and 
normal cells, mTOR2 maintains actin  organization by 
activating paxillin, F-actin  stress fibers, Rac1, RhoA, Cdc42, 
and protein kinase Cα. Consequently, its dysregulation is 
associated with cancerous cell migration and invasion 
(Holroyd, and Michie, 2018). Both mTORC1, and mTORC2 
are regulated by phosphorylation, complex formation, and 
localization. The mTOR pathway is regarded as the central 
regulator of mammalian physiology and metabolism with 
important roles in the functioning of diverse organs, in various 
cancers, and human diseases where it was found to be 
dysregulated (Giguère, 2018). 
 
G Protein-coupled receptors (GPCRs) Signaling Pathways 
WNT Signaling Pathway 
 
This pathway comprises various members of secreted lipid-
modified signaling glycoproteins that orchestrate and influence 
a myriad of biological, and developmental processes in the cell. 
Hyperactivation of the WNT pathway leads to the progression 
of various types of cancers, including melanoma (Willert and 
Nusse, 2012). WNT is a glycoprotein that is the cognate 
lingand of FZD receptors. The binding of WNT with FZD 
receptors initiates three possible pathways including (i) a 
classical intracellular signal transduction pathway that depends 
on β-catenin, (ii) a non- classical signal transduction pathway 
that although not dependent on β-catenin, however, controls 
cell polarity, and (iii) a WNT, and protein Kinase-C (PKC)-
dependent pathway. Both classical and non- classical WNT 
signaling pathways regulate tumor progression at different 
stages. Whereas the non-classical pathway mainly regulates 
cancer metastasis, while the classical pathway mainly works to 
transform melanocytes into melanoma (Paluncic et al., 2016). 
  
The Classical WNT Pathway 
 
The mechanism of this pathway is based on transcription factor 
β-catenin regulation via activation, and degradation. In the 
absence of WNT signaling, axin interacts with β-catenin 
adenomatous polyposis coli (APC), glycogen synthase kinase 
3β (GSK3β), and casein kinase 1α (CK1α) with separate 
domains to make a complex. These complex is able to 
coordinate a sequential phosphorylation of β-catenin, CKI, and 
GSK3, thus targeting them for ubiquitination, and subsequent  
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 degradation by the proteasome (Paluncic et al., 2016). However, 
when WNT, together with its co-receptor the low-density-
lipoprotein-related proteins 5/6 (LRP5/6), binds with the FZD 
receptor on cell membrane, β-catenin is released from the complex, 
and stabilizes it in the cytosol. From the cytosol it is subsequently 
translocated into the nucleus, where it transcribes WNT-responsive 
genes, including cyclin D1, and c-MYC, and ZEB-1 (Kaur, Webster 
and Weeraratna, 2016). 
 
ROS Mediated Pathways of Cell Migration and Metastasis and 
Proliferation 
 
Not only activation of kinases via phosphorylation can result in cell 
transformation, survival, and proliferation, but oxidants have also 
been shown to trigger the phosphorylation cascades of MAPKs and 
PI3K/ATK pathways. Three MAPKs pathways are extracellular 
signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and 
p38 MAPK. They are structurally related but functionally distinct 
kinases, considered to be modulated by cellular redox balance. In 
addition to cytokine and growth factor receptors activation, their 
activation results in uncontrolled cell proliferation, and survival. 
ERKs are activated by mitogens, while JNK and p38 MAPK can be 
activated by heat shock proteins, inflammatory cytokines, and ROS 
(Zhao, Wang, and Tony 2015). These pathways are activated by 
different threshold of ROS. A high level of ROS activates JNK and 
NF-κB pathways while p38 MAPK-related known to induce EMT 
including epidermal growth factor receptor (EGFR). Activation of 
NF-κB and AP-1 and c-Jun transcription factors induce the 
production of proteins, involved in cell proliferation, differentiation, 
inflammation, inhibition of apoptosis, and transformation (Son et al., 
2011). 
 
Melanoma Metastasis 
 
90% of all cancer deaths can be attributed to metastasis, and not to 
the primary tumors. In this process, cancerous cells attack adjacent 
tissues, and spread to distant organs (Steeg, 2016). Cancer metastasis 
is based on highly complex molecular, and cell biological principles, 
collectively referred to as ‘metastatic factors (Leber and Efferth, 
2009). Following steps are involved in the development of a 
secondary tumor from the primary tumor. 
 
Epithelial–Mesenchymal Transition 
The biological process of epithelial–mesenchymal transition (EMT) 
is the initial step of developing metastatic potential. This event alters 
the adhesive properties between melanocytes and keratinocytes, with 
subsequent morphological changes from an epithelial to a 
mesenchymal phenotype, cell motility, and loss of polarity, that 
permit tumor cells to outflow from their micro environment, and to 
migrate to distant locations via circulatory blood or lymphatic 
systems where in a visceral organ, they create a metastasis (Mittal, 
2018). The process of EMT is characterized by downregulation of 
several calcium-dependent adhesion molecules. Most prominently 
these molecules are E cadherins, claudins, occludin or catenin, and 
cytokeratins proteins. 
However, several mesenchymal proteins have been observed 
to be upregulated during EMT process, which confers the 
ability to detach from extracellular matrix to a melanoma cell, 
and migrate out of its nascent environment. The process of 
melanoma development lies on two basic early steps: 
disruption of adhesive interaction between melanocytes, and 
keratinocytes during EMT, and the invasion and migration of 
melanoma cells. These processes are regulated by N and E 
cadherins. In addition to transforming growth factor receptor 
signaling pathways, there are also numerous receptor tyrosine 
kinase signal transductions pathways that are known to induce 
EMT including epidermal growth factor receptor (EGFR). 
 
Cell Migration and Invasion 
Cell migration is the process of cell movement from one place 
to the other in response to chemical signals. Cells are packed 
together with the help of adhesive proteins at different adhesion 
sites (Khalili and Ahmad, 2015). These adhesion sites include 
focal complexes and focal adhesion complexes. Focal adhesion 
complexes are integrin-containing, multi-protein complex at 
cell adhesion sites (Burridge and Guilluy, 2016). These 
proteins create links between intracellular actin, and the 
extracellular substrate. To initiate migration of cells the activity 
of these proteins need to be altered that results in modification 
of the cell shape and stiffness, and initiate migration (Khalili 
and Ahmad, 2015). Cells migrate in both normal and 
pathological processes due to the coordinated and dynamic 
regulation of these adhesions sites under the influence of signal 
transduction pathways. Signals for cell migration, 
proliferation, and apoptosis are generated outside the cells 
when integrin clusters at the cell surface, and growth factor 
receptor binds to cognate growth factors (Mitra and Schlaepfer, 
2006; Chen et al., 2018; Marlowe et al., 2016). These signals 
then activate a non-receptor, non-membrane tyrosine kinase of 
the focal complex termed focal adhesion kinase (FAK) by 
phosphorylation of its autophosphorylation site (Tyrosine 397 
residue). After phosphorylation, tyrosine 397 focal adhesion 
kinase generates a high-affinity docking site for the SH2 
domain of Src family kinases. Consequently, it interacts with 
Src and makes an activated Src-FAK complex. The activated 
Src-FAK, in addition to the phosphorylation of multiple 
tyrosine residues Y576, Y577, Y925 of FAK, also 
phosphorylates other signaling molecules, such as p130Cas 
and paxillin. This cascade of phosphorylations results in cell 
cytoskeletal changes, and activation of other signaling 
pathways of cell migration, invasion, and metastasis (Zhao and 
Guan, 2011; Mitra, Hanson and Schlaepfer, 2005). The Y397 
site is one of the main phosphorylation sites that regulate a 
multitude of cellular processes involved in cancer metastases 
through FAK signaling in the cells. Therefore, FAK is 
considered as the master regulator protein due to its ability to 
mediate primarily cell migration, in addition to cell survival, 
apoptosis, and proliferation (Tai, Chen, and Shen, 2015). Thus, 
inhibiting the activity of FAK by dephosphorylating its Y397 
residue represents an excellent approach for 
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 treating cancer metastasis (Golubovskaya et al., 2008). Besides focal 
adhesion kinase, other mitogen-activated protein kinases (MAPKs), 
including Jun N-terminus kinase (JNK), p38, and ERK, are also 
considered as essential pathways of cell migration (Sun et al., 2015). 
 
Intravasation 
The penetration of endothelial cells by cancerous cells is under the 
effect of proteases that degrade the endothelium, and permit the cells 
to penetrate into the blood vessels 
 
Circulation 
Migration of cancer cell in lymphatic or blood vessel to a distant 
tissue takes place when cancer cells acquire anchorage independent 
proliferation. 
 
Extravasation 
In this step of metastasis, tumor cells migrate out of vessels into 
organs. An adhesion molecule of the immunoglobulin superfamily 
CD146 melanoma cell adhesion molecule MCAM is present at both 
endothelial junctions and tumor-endothelial contact sites, where it 
regulates the melanoma cell extravasation.  
 
Colonization 
To settle at a new location away from the primary tumor, cancer cells 
use diverse steps and overcome several hurdles, including infiltration 
into distant tissues, evading immune defenses, adapting to supportive 
niches, surviving as latent tumor-initiating seeds, eventually breaking 
out to replace the host tissue. All this makes metastasis a highly 
ineffective process. 
 
Metastatic Melanoma Treatment Options 
 
Systemic therapies are provided by medications that spread in the 
body to treat cancer cells at all possible locations. These therapies are 
used in stage IV melanoma patients. They include cytotoxic 
chemotherapy, targeted drugs, immunotherapy, hormonal therapy, 
and bio-chemotherapy (Bhatia, Tykodi, and Thompson, 2009). 
 
Metastatic Melanoma Cytotoxic Chemotherapy 
Cytotoxic chemotherapy has been used since last three decades for 
the treatment of metastatic melanoma, and aims at preventing or 
relieving symptoms. Few chemotherapeutic agents with modest 
antitumor efficacy have been used for the treatment of metastatic 
melanoma alone or in combination (Bhatia, Tykodi, and Thompson, 
2009). 
 
Single Agent Cytotoxic Chemo Therapy 
Dacarbazine is an alkylating agent, and the only standard single 
chemotherapeutic drug for metastatic melanoma treatment with a 
significant survival benefit. This drug represses gene transcription by 
methylating guanine N-7 or O-6 positions. Although there are some 
other chemotherapeutic drugs that have been approved by US-FDA 
for metastatic melanoma, no other therapy has yet shown a similar or 
greater efficacy over dacarbazine (Hill, Krementz, and Hill, 1984). 
 
Despite some common side effects like mild nausea and 
vomiting, myelosuppression, and fatigue, most patients are 
able to maintain their basic quality of life with dacarbazine 
(Bhatia, Tykodi, and Thompson, 2009).  
 
Temozolomide is an analog of dacarbazine. It has the same 
mechanism of action like dacarbazine, and has been 
investigated extensively in metastatic melanoma due to its 
excellent oral bioavailability, and ability for CNS penetration 
(Patel et al., 2011; Chiarion-Sileni, 2008). 
 
Anti-microtubular agents, i.e., Vinca alkaloids (vincristine, 
vinblastine), and taxanes (paclitaxel, and nab-paclitaxel) are 
anti-microtubule agents. They exhibit modest activity in 
patients with metastatic melanoma. These agents used 
sometimes in combination with cytotoxic chemotherapy or 
biochemotherapy regimens (Nathan Berd, and Mastrangelo, 
2000). 
 
Platinum analogs interfere with DNA replication. In metastatic 
melanoma, platinum drugs cisplatin and carboplatin have 
limited activity (Evans, Casper, and Rosenbluth, 1987).  
 
Nitrosoureas are comparable to dacarbazine with more 
myelosuppression and alopecia. This class of drug includes 
carmustine (BCNU), lomustine (CCNU), and fotemustine, that 
can be used as single agents. Patients with brain metastases are 
effectively treated with fotemustine (Khayat et al., 1994). 
 
Combination Chemotherapy 
The modest anti-tumor activity of the chemotherapeutic agents, 
mentioned in the preceding sections has led to the investigation 
of their combinations. Studies have been conducted to 
investigate chemotherapy in terms of response rate, and 
possibly survival. 
 
The Dartmouth regimen is combination of four drugs, cisplatin, 
dacarbazine, carmustine, and tamoxifen (Del Prete et al., 
1984). However, Dartmouth regimen did not show a 
statistically significant benefit in favor of the combination vs. 
dacarbazine monotherapy in a phase III randomized clinical 
trial (Chapman et al., 1999). 
 
CVD regimen, is a regmen that includes vinblastine, cisplatin, 
and dacarbazine  and used for the treatment of advanced-
stage melanoma (Legha et al., 1989; Legha et al., 1996). 
 
Paclitaxel and carboplatin (PC) regimen in both metastatic 
melanoma patients, and patients who have received prior 
chemotherapy, has been used as a combination therapy (Hodi 
et al., 2002).  
 
Pro-apoptotic drugs regimen is a combination of cisplatin, with 
5-fluorouracil (5-FU). This is the recent major form of 
proapoptotic drug treatment, used in the clinical management 
of different types of cancers, including melanomas (Mattia et 
al., 2018). 
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Metastatic Melanoma Immunotherapy 
It includes interleukin-2 and interferon alfa-2b for treating 
metastatic melanoma by enhancing immune response against the 
tumor cells (Martin and Lo, 2018; Atkins et al., 1999; Creagan et 
al., 1986) 
 
Metastatic Melanoma Targeted Therapies 
These therapies include BRAF-inhibitors vemurafenib that 
interferes with the B-Raf/MEK/ERK pathway, dabrafenib that 
inhibits some malformed BRAF kinases, and trametinib for 
inhibiting MEK-1/2. 
 
Metastatic Melanoma Bio-Chemo-therapy 
Biochemotherapy combines the use of cytotoxic agents with IFN-α 
and/or IL-2. Although biochemotherapy compared to chemotherapy 
alone provides increased response rate in patients who have rapidly 
progressing disease, due to toxicities associated with 
biochemotherapy, together with its insignificant survival 
alternatives, such as HD IL-2 or other agents, are used for patients 
who suffer from chronic melanoma (Ives et al., 2007: Lui et al., 
2007). 
 
Novel Therapies under Investigation 
Currently, anti-CTLA-4 anti-body, adoptive cell therapy, and 
vaccination are being used as novel approaches. Certain vaccines, 
based on peptides (e.g., gp100), nucleic acids (e.g., Allovectin-7), 
dendritic cells, and heat shock protein complexes (e.g., vitespen), 
have given encouraging results in phase II and phase III clinical 
trials (Richards et al., 2005; Dudley et al., 2008). Even with these 
available treatment options, metastatic melanoma still presents itself 
as an incurable disease.  
 
Conclusion 
 
In order to obtain a successful treatment of aggressive cancer, it is 
important to develop, and use new approaches for metastatic 
melanoma prevention, and treatment in cases of refractory 
treatments. Various new therapeutic agents have been developed 
against various protein kinases, that are considered as molecular 
players of the currently investigated pathways described above. 
They are known to be involved in metastatic melanoma. Some of the 
new therapeutic interventions against these kinases have 
successfully reached clinical trials (Harris et al., 2016) while others 
already have been approved by the US-FDA. However, due to the 
emergence of resistance against these drugs, and the adverse effects 
they cause, multiple phases II and III melanoma trials are currently 
underway that are either studying the effect of combination 
treatments, or new synthetic and natural compounds as new possible 
treatment options. However, no systemic therapy has meaningfully 
changed these survival end points so far, and there is still a need to 
prevent the induction of melanoma or develop combination 
therapies that target the unique molecular profile of melanoma 
tumors. Additionally, there is also need for identification of new 
synthetic, and natural compounds as new treatment options. 
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